Патогенез нарушений системы гемостаза при кардиохирургических операциях
По данным Bick RL. и Fareed J. (1997) тип оксигенатора играл незначительную роль по сравнению с другими причинами возникновения клинически значимой тромбоцитопении. Тромбоцитопения была более выражена при использовании пузырькового оксигенатора, по сравнению с мембранным, но это различие клинически не было значимым. Более весомыми причинами возникновения тромбоцитопении при операциях с ИК… Читать ещё >
Содержание
- Общая характеристика работы
- Введение. Патология гемостаза при кардиохирургических операциях
- Глава 1. Характеристика больных и методы исследования
- 1. 1. Характеристика больных
- 1. 2. Приготовление анализируемых образцов крови
- 1. 3. Лабораторные методы исследования
- 1. 4. Статистическая обработка материала
- Глава 2. Проблемы «искусственной гемофилии» и ее нейтрализации в кардиохирургии
- 2. 1. Тактика и мониторинг «искусственной гемофилии» при операциях в условиях искусственного кровообращения
- 2. 2. Тактика и мониторинг нейтрализации антикоагуляции после операций в условиях искусственного кровообращения
- 2. 3. Феномен рикошетного эффекта гепарина
- 2. 4. Осложнения, связанные с введение протамина
- 2. 5. Альтернативные средства и методы нейтрализации гепарина
- Глава 3. Состояние системы гемостаза при операциях с искусственным кровообращением
- 3. 1. Влияние состава первичного объема заполнения аппарата искусственного кровообращения
- 3. 2. Влияние температурных режимов искусственного кровообращения на систему гемостаза
- 3. 3. Влияние технических характеристик экстракорпоральных контуров на тромбоцитарный гемостаз
- 3. 4. Влияние технических характеристик экстракорпоральных контуров и условий искусственного кровообращения на систему фибринолиза
- 3. 5. Влияние условий искусственного кровообращения на изменение факторов плазменного звена гемостаза
- 3. 6. Влияние условий искусственного кровообращения на эндогенные антикоагулянты
- 3. 6. 1. Влияние длительности и температурных режимов искусственного кровообращения
- 3. 6. 2. Влияние специального покрытия экстракорпорального контура
- 3. 7. Влияние миниэкстракорпоральных контуров на систему гемостаза
- Глава 4. Состояние гемостаза при кардиохирургических операциях без искусственного кровообращения
- 4. 1. Состояние гемостаза при операциях аортокоронарного шунтирования без искусственного кровообращения
- 4. 2. Состояние гемостаза при операциях на аорте без искусственного кровообращения
- Глава 5. Причины и прогноз повышенной кровоточивости после кардиохирургических операций
- 5. 1. Роль нарушений плазменного звена гемостаза в генезе повышенной послеоперационной кровоточивости
- 5. 2. Нарушения тромбоцитарного звена гемостаза как причина повышенной кровоточивости
- 5. 3. Роль системы фибринолиза в генезе повышенной кровоточивости
- 5. 4. Феномен «heparin-rebound»
- 5. 5. Структура повышенной послеоперационной кровоточивости
- 5. 6. Прогноз послеоперационной кровопотери
- Глава 6. Фармакологическая профилактика и коррекция нарушений гемостаза при операциях на сердце и аорте
- 6. 1. Антифибринолитические препараты
- 6. 1. 1. Апротинин
- 6. 1. 1. 1. Влияние апротинина на систему гемостаза
- 6. 1. 1. 2. Использование больших (6 млн. ЕИК) доз апротинина при операциях с искусственным кровообращением
- 6. 1. 1. 3. Использование низких (2 млн. ЕИК) доз апротинина при операциях с искусственным кровообращением
- 6. 1. 1. 4. Использование апротинина при операциях на аорте
- 6. 1. 1. 5. Осложнения, возникающие при использовании апротинина
- 6. 1. 2. Аминокапроновая кислота
- 6. 1. 3. Сравнительная оценка эффективности апротинина и £-аминокапроновой кислоты в снижении кровопотери после операций с искусственным кровообращением
6.2. Рекомбинантный активированный фактор свертывания VII в лечении массивных кровотечений нехирургического генеза во время и после кардиохирургических операций 156 6.2.1. Эффективность и безопасность применения рекомбинантного активированного фактора VII
6.2.2. Состояние системы гемостаза при терапии рекомбинантным активированным фактором VII
6.2.2.1. Плазменное звено гемостаза
6.2.2.2. Система естественных антикоагулянтов
6.2.2.3. Тромбоцитарное звено гемостаза
6.2.2.4. Система фибринолиза 168 6.2.3. Использование рекомбинантного активированного фактора VII при остром синдроме ДВС
6.2.4. Использование рекомбинантного активированного фактора VII при обходе левого желудочка
6.2.5. Влияние рекомбинантного активированного фактора VII на объем гемотрансфузий 177
Заключение 181
Выводы 194 Практические рекомендации 197
Литература
ОБЩАЯ ХАРАКТЕРИСТИКА РАБОТЫ
- 6. 1. 1. Апротинин
- 6. 1. Антифибринолитические препараты
Список литературы
- Акчурин P.C., Ширяев A.A., Галяутдинов Д. М., Сагиров М. А. Результаты реваскуляризации миокарда без искусственного кровообращения. // Тезисы IX Всероссийского съезда сердечно-сосудистых хирургов, Москва, 18−23 ноября, 2003 -с. 203.
- Баркаган З.С. Геморрагические заболевания и синдромы. // М., Медицина 1988. — с. 28−31.
- Баркаган З.С., Момот А. П. Диагностика и контролируемая терапия нарушений гемостаза // Ньюдиамед. М. — 2001. — 184 с.
- Гемостаз. Физиологические механизмы, принципы диагностики основных форм геморрагических заболеваний. / под ред. Петрищева H.H., Папаян Л. П. // СПб. -1999.-е. 18−19.
- Дементьева И.И., Чарная М. А., Кротовский А. Г., Шабалкин Б. В., Морозов Ю. А. Влияние больших доз апротинина на дисфункцию шунтов после операций АКШ // VIII Всероссийский съезд сердечно-сосудистых хирургов, Москва, 18−22 ноября, 2002-с. 89.
- Дементьева И.И., Чарная М. А., Морозов Ю. А., Трекова H.A. Использование гемостатика НовоСэвен®- у больных с массивной геморрагией при крупных хирургических вмешательствах. / Пособие для врачей. // М., МАКС Пресс. 2004. -32 с.
- Зацепина Н.Е. Влияние искусственного кровообращения на перекисное окисление липидов. // Дисс. канд. мед. наук. М. — 2001. — 124 с.
- И. Клиническая лабораторная аналитика, т. III Частные аналитические технологии в клинической лаборатории. / Под ред. Меньшикова В. В. // М., Лабпресс. 2000. — с. 316−345.
- Лакин Г. Ф. Биометрия. // М., Высшая школа. 1990. — 352 с.
- Локшин Л.С., Лурье Г. О., Дементьева И. И. Искусственное и вспомогательное кровообращение в сердечно-сосудистой хирургии. // М. 1998. — 212 с.
- Лоуренс Д.Р., Бенитт П. Н. Клиническая фармакология. // М., Медицина. 1991. — т. 1.-е. 524−552.
- Ляпина Л.А., Пасторова В. Е., Каминский A.A. и др. Комплекс гепарин-«Семакс», его влияние на антикоагулянтные и фибринолитические свойства плазмы крови животных // Вопр. биол. мед. и фарм. химии. 2000. — № 3. — с.33−35.
- Максименко В.Б. Коррекция критических состояний и профилактика осложнений при операциях на сердце с искусственным кровообращением. // Автореф. дисс. докт. мед. наук. Киев. — 1990. — 40 с.
- Момот А.П. Патология гемостаза. Принципы и алгоритмы клинико-лабораторной диагностики. // ФормаТ. СПб. — 2006. — 208 с.
- Морозов Ю.А. Система фибринолиза после операций на сердце в условиях искусственного кровообращения. //Дисс. канд. мед. наук. -М. 2006. — 126с.
- Морозов Ю.А., Чарная М. А., Гладышева В. Г. Влияние аминокапроновой кислоты и малых доз апротинина на кровопотерю после операций в условиях искусственного кровообращения. // Анестезиология и реаниматология. 2005. — № 4. — с.58−60.
- Осипов В.П. Основы искусственного кровообращения. // М., Медицина. 1976. -238 с.
- Панченко Е.П., Добровольский А. Б. Тромбозы в кардиологии. Механизмы развития и возможности терапии. // М., Спорт и культура. 1999. — с. 60−70.
- Савина М.Э. Активированное время свертывания в оценке адекватности гепаринизации и нейтрализации гепарина при операциях с искусственным кровообращением. // Дисс. канд. мед. наук. М. — 1986. — 229 с.
- Сидельников С.Г. Некоторые аспекты управления гемостазом у больных ИБС, оперированных в условиях искусственного кровообращения.// Автореф. дисс. канд. мед. наук. Новосибирск. — 2000. — 16 с.
- Сидор Н.В., Момот А. П. Фактор XIII: структура, функция, методы определения, роль в патологии человека. // Тромбоз, гемостаз и реология. 2003. — № 1. — с. 10−21.
- Скипетров В.П., Власов А. П., Голышенков С. П. Коагуляционно-литическая система тканей и тромбоэмболический синдром в хирургии. // Саранск. 1999. — с. 111−132.
- Трекова Н.А., Соловова Л. Е., Кузнецов Р. В., Асмангулян Е. Т. Эпидемиология и профилактика анафилактоидных реакций у кардиохирургических больных. // Анестезиология и реаниматология. 2000. — № 5. — с. 21−25.
- Чарная М.А. Патофизиологические аспекты применения больших доз апротинина при операциях с искусственным кровообращением. // Дисс.канд. биол. наук. М. -1993.-c.145.
- Чарная М.А., Морозов Ю. А., Гладышева В. Г., Крапивкин И. А. Влияние технических характеристик экстракорпоральных контуров на тромбоцитарное звено гемостаза, систему фибринолиза и развитие гемолиза. // Вестник РАМН. 2005. — № 10. — с. 1215.
- Шитикова А.С. Тромбоцитарный гемостаз. // СПб., Изд-во СПб ГМУ. 2000. — 227 с.
- Яровая Г. А., Блохина Т. Б., Нешкова Е. А. Механизмы активации контактной системы. Новые факты и концепции. // Тромбоз, гемостаз и реология. 2003. — № 4(16).-с. 16−24,
- Adams Т., Schutz L., Goldberg L. Platelet function abnormalities in myeloproliferative disorders. // Scand. J. Haematol. 1975. — vol. 13. — p. 215.
- Alderman E.L. Drug therapy before coronary artery operations. // J Thorac Cardiovasc Surg. 1999. — vol. 118(5). — p. 979−980.
- Ammar T., Fisher CF. The effects of heparinase 1 and protamine on platelet reactivity. // Anesthesiology. 1997. — vol. 86(6). — p. 1382−1386.
- Ammar T., Scudder LE., Coller BS. In vitro effects of the platelet glycoprotein Ilb/IIIa receptor antagonists c7E3 Fab on the activated clotting time. // Circulation. 1997. — vol. 95.-p. 614−617.
- Aprile AE., Palmer TJ. The intraoperative use of Amicar to reduce bleeding associated with open heart surgery. // AANA J. 1995. — vol.63. — p.325.
- Ashraf S, Tian Y, Cowan D, Nair U, Chatrath R, Saunders NR, Watterson KG, Martin PG. «Low-dose» aprotinin modifies hemostasis but not proinflammatory cytokine release. // Ann. Thorac. Surg. 1997. — vol. 63(1). — p. 68−73.
- Barrons R.W., Jahr J.S.A., Review of post-cardiopulmonary bypass bleeding, aminocapronic acid, tranexamic acid and aprotinin. // Am. J. Ther. 1996. — N 3 (12). — p. 821−838.
- Belboul A., al-Khaja N. The effect of protamine on the epicardial microflow and the graft flow in open-heart surgeiy. // Perfusion. 1997. — vol. 12(2). — p. 99−106.
- Bert A.A., Steams G.T., Feng W. Normothermic Cardiopulmonary Bypass // J. of Cardiothoracic and Vascular Anesthesia. 1997. — Vol. 11(1),. — p. 91−99.
- Bick RL. Syndromes associated with hyperfibrino (geno)lysis. // In book: Disseminated intravascular coagulation (ed. Bick RL.). Boca Raton, FL, CRC Press. — 1983. — p. 105.
- Bick RL. Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits. // Semin. Thromb. Hemost. 1985. — vol.11. — p.249−280.
- Bick RL. Platelet defects // In book: Disorders of hemostasis and thrombosis: principles of clinical practice (ed. Bick RL.). NY. Thieme. — 1985. — p.65.
- Bick RL. Disseminated intravascular coagulation and related syndromes: a clinical review. // Semin. Thromb. Hemost. 1988. — vol.14. — p.299.
- Bick RL. Alterations of hemostasis associated with surgery, cardiopulmonary bypass surgery, prosthetic devices and transplantation. // In book (ed. Ratnoff OD., Frobes CD.) Disorders of hemostasis, 2nd ed. Philadelphia, WB. Saunders. — 1991. — p.382.
- Bick RL. Assessment of patients with hemorrage. // In book Bick RL. (ed) Disorders of thrombosis and hemostasis: Clinical and laboratory practice. Chicago, ASCP Press. -1992.-p.27.
- Bick RL. Disseminated intravascular coagulation. // In book Bick RL. (ed) Disorders of thrombosis and hemostasis: Clinical and laboratory practice. Chicago, ASCP Press. -1992.-p. 137.
- Bick RL. Hemostasis defects with cardiac surgery, general surgery, and prosthetic devices. // In book Bick RL. (ed) Disorders of thrombosis and hemostasis: Clinical and laboratory practice. Chicago, ASCP Press. — 1992. — p. 195.
- Bick RL. Heparin therapy monitoring: Guidelines and practice parameters for clinical and laboratory approaches. // J. Clin. Appl. Thromb. Hemost. 1996. — vol. 2 (suppl. 1). — p. 12.
- Bick RL. Thrombotic and hemorrhagic problems during CPB surgery. // In book Management of bleeding in cardiovascular surgery (ed. Piffare R.). Hanley & Belfus, Inc., Philadelphia. — 2000. — p.9−63.
- Bick RL., Adams T., Schmalhorst WR. Bleeding times, platelet adhesion, and aspirin. // Am. J. Clin. Pathol. 1976. — vol. 65. — p. 69.
- Bick RL. Arbegast NR., Crawford L., et al. Hemostatic defects induced by cardiopulmonary bypass. // Vase. Surg. 1975. — vol.9, -p.228.
- Bick RL., Faizer BL., Saunders CL., Arbegast NR. Alteration of hemostasis durin cardiopulmonary bypass: The potential role of factor XII activation in inducing primary fibrino (geno)lysis. // Blood.- 1984. vol.64, -p.926.
- Bick RL., Fareed J. Hemostasis processes during cardiovascular bypass and intravascular cardiovascular devices. // In book New anticoagulants for the cardiovascular patients (ed. Pifarre R.). Philadelphia, Hanley & Belfus. — 1997. — p.551.
- Bick RL., Scharnhorst WR., Arbegast NR. et al. Alteration of hemostasis association with cardiopulmonary bypass. // Am. J. Clin. Pathol. 1975. — vol. 63. — p. 588.
- Bick RL., Schmalhorst SW., Arbegast NR. Alterations of hemostasis associated with cardiopulmonary bypass. // Thromb. Res. 1976. — vol.8. — p.285.
- Bick RL., Tse N. Hemostasis abnormalities with prosthetic devices and organ transplantation. // Lab. Med. 1992. — vol. 23. -p. 462−486.
- Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Effect of aprotinin on need for blood transfusion in patients with septic endocarditis having open heart surgery. // Lancet. -1988.-Nl.-p. 366−367.
- Blomback M., Noren I., Senning A. Coagulation disturbances during extracorporeal circulation and the postoperative period. // Acta Chir. Scand. 1964. — vol. 127. — p. 433.
- Blome M, Isgro F, Kiessling AH, Skuras J, et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening test and postoperative bleeding in cardiopulmonary bypass surgery. //Thromb Haemost. 2005. — vol.93(6). -p.l 101−1107.
- Boinot C., Lanquetot H., Macchi L., Charriere J.M., Menu P. Lepirudin during cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. // Ann. Fr. Anesth. Reanim. 2003. — vol. 22(7). — p. 635−638.
- Boldt J, Knothe C, Welters I, Dapper FL, Hempelmann G. Normothermic versus hypothermic cardiopulmonary bypass: do changes in coagulation differ? // Ann Thorac Surg. -1996. -vol.62(l).-p.130−135.
- Boldt J, Knothe C, Zickman B. Platelet function in cardiac surgery: Influence of temperature and aprotinin// Ann Thorac Surg. 1993. — vol. 55. — p. 652 — 658.
- Boldt J., Schindler E., Knothe C., Welters I. Sternmann WA., Hempelmann G. Endothelial-related coagulation in cardiac surgery. // Br. J. Anaesth. 1995. — vol. 74(2). -p. 174−179.
- Boldt J., Zickmann B., Ballesteros BM., Stertmann F., Hampelmann G. Influence of five different priming solutions on platelet function in patients undergoing cardiac surgery. // Anesth. Analg. 1992. — vol. 74(2). — p. 219−225.
- Bowie EJW., Owen CA. The value of measuring platelet adhesiveness in the diagnosis of bleeding diseases. // Am. J. Clin. Pathol. 1973. — vol. 60. — p.302.
- Bowie EJW., Owen CA., Thompson JH. Platelet adhesiveness in von Willebrand’s disease. // Am. J. Clin Pathol. -1969. vol.52. — p.69.
- Brooks JC. Noncardiogenic pulmonary edema immediately following rapid protamine administration. // Ann. Pharmacother. 1999. — vol. 33(9). — p. 927−930.
- Brooks DH., Bahnson HT. An outbreak of hemorrhage following cardiopulmonary bypass. // J. Thorac. Cardiovasc. Surg. 1972. — vol.63. — p.449.
- Brookes CI., Fry CH. Ionised magnesium and calcium in plasma from healthy volunteers and patients undergoing cardiopulmonary bypass. // Br. Heart J. 1993. — vol 69(5). -p.404−408.
- Casati V., Gerli C., Franco A., Delia Valle P., Benussi S., Alfieri O., Torn G., D’Angelo A. Activation of coagulation and fibrinolysis during coronary surgery: on-pump versus offpump techniques. // Anesthesiology. 2001. — vol. 95 (5). — p. 1103−1109.
- Chan KK SE., Hood PA. et al. Heparin concentration measured by protamine titration versus high-dose thrombin time in the presence of aprotinin. // Anesth. Analg. 1998. -vol. 86.-p. SCA56.
- Chandler W. The effects of cardiopulmonary bypass on fibrin formation and lysis: is a normal fibrinolytic response essential? // J. Cardiovasc. Pharmacol. 1996. — vol. 27, suppl. l.-p. S63-S68.
- Chandler W., Fitch JC., Wall MN., Verrier ED., Cochran RP., Soltow LO., Spiess D. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. //Thromb. Haemost.- 1995. -vol. 74 (5).-p. 1293−1297.
- ChandlerWL., Patel MA., Gravelle L., Soltow LO., Lewis K" Bishop PD., Spiess BD. Factor XHIa and clot strength after cardiopulmonary bypass. // Blood Coagul. Fibrinolysis. 2001. — vol. 12(2). — p. 101 -108.
- Chang LC., Lee HF., Chung MJ., Yang VC. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation.//Bioconiug. Chem.-2005.-vol. 16(1).-p. 147−155.
- Codispoti M., Ludlam CA., Simpson D., Mankad PS. Individualized heparin and protamine management in infants and children undergoing cardiac operation. // Ann. Thorac. Surg. -2001.-vol. 71(3).-p. 922−927.
- Conney A., Mann TJ. Recent experiences with hexadimethrine for neutralizing heparin after cardiopulmonary bypass. // Anesth. Intensive Care. 1999/ - vol. 27(3). — p. 298−300.
- Culliford AT., Gitel SN., Starr N. et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. // Ann. Surg. 1981. — vol. 193. — p. 105−111.
- Dale J, Lilleaasen P. Cardiopulmonary bypass and hemostasis. // Abstr. 8 Scand. Congr. of cardiol. Stockholm. — 1982. — p.56.
- Deiter RA., Neville WE., Piffare R., Jasuja M. Preoperative coagulation profiles and posthemodilution cardiopulmonary bypass hemorrage. // Am. J. Surg. 1971. — vol.121. -p. 689.
- Derman UM., Rand PW., Barker N. Fibrinolysis after cardiopulmonary bypass and its relatonship to fibrinogen. // J.Thorac. Cardiovasc. Surg. 1966. — vol.51. — p. 223.
- Despotis G.J., Avidan M.S., Hogue C.W.-Jr. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation // Ann. Thorac. Surg. 2001. — vol. 72(5). — p. SI821- SI831.
- Despotis GJ, Joist JH. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update. // J Cardiothorac Vase Anest. 1999. -vol.13 (4 Suppl 1).-p. 18−29.
- Dietrich W., Braun S., Spannagl M., Richter JA. Low preoperative antithrombin activity causes insufficient heparin in adult but not in infant cardiac surgery. // Anesth. Analg. -2001.-vol. 92(1).-p. 66−71.
- Dietrich W, Spath P, Ebell A, et al. Prevalence of anaphylactic reactiona to aprotinin: Analysis of two hundred forty-eigth reexposures to aprotinin in heart operations. // J Thorac Cardiovasc Surg. 1997. — vol.113. -p. 194−201.
- Edwards JT., Hamby JK., Wirrall NK. Succesful use of Argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiak surgical patient. // Ann. Thorac. Surg. 2003. — vol. 75(5). — p. 1622−1624.
- Eisses MJ, Seidel K, Aldea GS, Chandler WL. Redusing hemostatic activation during cardiopulmonary bypass: a combined approach. // Anesth Analg. 2004. — vol.98(5). -p.1208−1216.
- Ellison N., Beaty P., Blake DR. et al. Heparin rebound. // J. Thorac. Cardiovasc. Surg. -1974.-vol. 67.-p. 723−729.
- Engelman RM., Pleet AB., Rousou JA. et al. The influence of cardiopulmonary bypass perfusion temperature on neurologic and hematologic function after coronary artery bypass grafting. // Ann. Thorac. Surg. 1999. — vol. 12. — p. 46−49.
- Engelman RM., Pleet AB., Rousou JA. et al. What is the best perfusion temperature for coronary revascularization? // J. Thorac. Cardiovasc. Surg. 1996. — vol. 112. — p. 16 221 632.
- Esposito RA., Culliford AT., Colvin SB., Thomas SJ., Lackner H., Spencer FG. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.//J. Thorac. Cardiovasc. Surg. 1983.-vol. 85(2).-p. 174−185.
- Evans D.A., Holder R.L., Brawn W.L., Sethia B. Post-operative blood loss following cardiopulmonary bypass in children // Eur. J. Cardiothorac. Surg. 1994. — vol. 8(1). — p. 25−29.
- Fiser WP., Read RC., Wright FF., Vecchio TJ. A randomized study of beef lung and pork mucosal heparin in cardiac surgery. // Ann. Thorac. Surg. 1983. — vol. 35(6). — p. 615 620.
- Forestier F., Belisle S., Robilaille D., Martineau R., Perrault L.P., Hardy J.F. Low-dose aprotinin is ineffective to treat excessive bleeding after cardiopulmonary bypass // Ann. Thorac. Surg. 2000. — vol. 69 (2). — p. 452−456.
- Frick PG., Brogli H. The mechanism of heparin rebound after extracorporeal circulation for open heart surgery. // Surgery. 1966. — vol. 59. — p. 721−726.
- Fritz H, Wunderer G, Jochum M. Biochemie und anrucndung des kallikrein-inhibitors aprotinin aus rinderorganen. // Arzneim.-Forsch/Drug Res. 1983. — vol.33(l). — p.479−494.
- Gallub S. Heparin rebound in open heart surgery. // Surg. Gynecol. Obstet. 1967. — vol. 127.-p. 337−346.
- Gitel S.N., Salvati E.A., Wessler S., Robinson H.J., Worth M.N. The effect of total hip replasement and general surgery on antithrombin III in relation to venous thrombosis. // J. Bone and Joint Surg. 1979. — vol. 61. — p. 653−656.
- Godje 0., Haushofer M., Lamm P., Reichart B. The effect of factor XIII on bleeding in coronary surgery. // Thorac.Cardiovasc. Surg. 1998. — vol.46 (5). — p.263−267.
- Gomes MM., McGoon D. Bleeding patterns after open heart surgery. // J.Thorac. Cardiovasc. Surg. 1970. — vol.60.- p.87.
- Graeff H., Beller FK. Fibrinolytic activity in whole blood, dilute blood, and euglobulin lysis time tests. // In book Thrombosis and bleeding disorders: Theory and methods, (eds. Bahg N., Beller FK., Deutsch E.). NY., Academic Press. — 1970. — p.328.
- Gravlee GP., Whitaker CL., Mark LJ. et al. Baseline activated coagulation time should be measured after surgical incision. // Anesth. Analg. 1990. — vol. 71. — p. 549−553.
- Greinacher A. The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia. // Semin. Thromb. Hemost. 2004. — vol. 30(3). -p. 315−327.
- Greinacher A., Michels I., Mueller-Eckhard C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. // Thromb. Haemost. 1992. — vol. 67. — p. 545−549.
- Grossmann R., Babin-Ebell J., Misoph M. et al. Changes in coagulation and fibrinolytic parameters caused by extracorporeal circulation. // Heart Vessels. 1996. — Vol. 11. — p. 310−317.
- Haddad R, Kesrouani C, Nasr W. Low-dose aprotinin in cardiac operations. // J Med Liban. -2000, — vol.48(3). -p.157−160.
- Haithcock BE., Shepard AD., Raman SB., Conrad MF., Pandurangi K., Fanous NH. Activation of fibrinolytic pathways is associated with duration of supraceliac aortic cross-clamping. // J Vase Surg. 2004. — vol.40, N2. — p.325−333.
- Halfman-Franey M., Berg DE. Recognition and management of bleeding following cardiac surgery. // Crit. Care Nurs. Clin. North. Am. 1991. — vol. 3, suppl. 4. — p. 675−689.
- Hardy JF, Belisle S, Couturier A, Robitaille D. Randomized, placebo-controlled, doubleblind study of an ultra-low-dose aprotinin regimen in reoperative and/or complex cardiac operations. // J Card Surg. 1997. — vol. l2(l). — p.15−22.
- Hardy J-F., Desroches J. Natural and synthetic antifibrinolytics in cardiac surgery. // Can. J. Anaesth. 1992. — vol. 39. — p. 353−365.
- Harkay F., Martin P., Rajah SM. et al. Response to heparinization in adults and childres undergoing cardiac operations. // Ann. Thorac. Surg. 1992. — vol. 53. — p. 822−826.
- Harker LA., Malpass TW., Branson HE. et al. Mechanisms of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective alfa-granule release. // Blood. 1980. — vol. 56. — p. 824.
- Heller EL., Paul L. Anticoagulation management in a patient with an acquired antithrombin III deficiency. // J. Extra Corpor. Thechnol. 2001. — vol. 33(4). — p. 245−248.
- Herwaldt LA, Swartzendruber SK, Zimmerman MB, Scholz DA, et al. Hemorrhage after coronary artery bypass graft procedures. // Infect Control Hosp Epidemiol. 2003. -vol.24(l). -p.44−50.
- Hirsh J. Laboratory diagnosis of thrombosis. // In book Colerman RW., HiTsh J., Marder VJ. (eds.) Hemostasis and thrombosis: basis principles and clinical practice. Philadelphia, J.B. Lippincott. — 1982. — pp.789.
- Horrow JC. Protamine: a review of its toxicity. // Anesth. Analg. 1985. — vol. 64(3). — p. 348−361.
- Hsu L.C. Heparin-coated cardiopulmonary bypass circuits: current status. // Perfusion. -2001.-vol. 16(5).-p. 417−428.
- Huff T., Otto AM., Muller CS., Meier M., Hannappel E. Thymosin beta4 is released from human blood platelets and attached by factor XHIa (transglutaminase) to fibrin and collagen. // FASEB J. 2002. — vol. 16(7). — p. 691−696.
- Hunt BJ., Parratt RN., Segal HC. et al. Activation of coagulation and fibrinolysis during cardiothoracic operation. // Ann. Thorac. Surg. 1998. — Vol. 65. — p. 712−718.
- Illing KA., Green RM., Ouriel K., Riggs PN., Bartos S., Whorf R., De Weese JA., Chibber A., Marder VJ., Francis CW. Primary fibrinolysis during supraceliac aortic clamping. // J. Vase. Surg. 1997. — vol/ 25(2). — p. 244−251.
- Jain U. Myocardial ischemia after cardiopulmonary bypass. // J. Card. Surg. 1995. — vol. 10.- № 4 (suppl.). — p. 520−526.
- Jansen PH, Lorand L, Ebbesen P, Gliemann J. Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XHIa. // Eur. J. Biochem. 1993. -vol. 214.-p. 141−146.
- Jones K., Nasrallah F., Darling E., Clay N., Searles B. The in vitro effects of aprotinin on twelve different ACT test. // J. Extra Corpor. Technol. 2004. — vol. 36(1). — p. 51−57.
- Kaplon RJ., Gillinov AM., SmediraNG., Kottke-Marchant K., Wang IW., Goormastic M" McCarthy PM. Vitamin K reduced bleeding in left ventricular assist device recipients. // J. Heart Lung Transplant. 1999. — vol. 18(4). — p. 346−350.
- Kaul TK., Crow MJ., Rajar SM., Deverall PB., Watson DA. Heparin administration during extracorporeal circulation: heparin rebound and postoperative bleeding.// J. Thorac. Cardiovasc. Surg. 1979.-vol.78 (1).-95−102.
- Kawasuji M, Ueyama K, Sakakibara N, Tedoriya T, Matsunaga Y, Misaki T, Watanabe Y. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass. // Ann Thorac Surg. 1993. — vol.55(5). -p.1205−1209.
- Kesteven PJ, Ahmed A, Aps C, Wiliams BT., Savidge GF. Protamine sulphate and heparin rebound following open-heart surgery. // J. Cardiovasc. Surg. (Totino). 1986. — vol. 27(5).-p. 600−603.
- Kevy SV., Glickman RM., Bernhard WF. et.al. The pathogenesis and control of the hemorrhagic defect in open-heart surgery. // Surg. Gynecol. Obstet. 1966. — vol.123. -p.313
- Kikura M., Lee MK., Levy JH. Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass. // Anest. Analg. 1996. -vol. 83(2).-p. 223−227.
- Kimmel SE., Sekeres M., Berlin JA., Ellison N. Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. // Anesth. Analg. 2002. — vol. 94(6). — p. 1402−1408.
- Kimmel SE., Sekeres MA., Berlin JA., Ellison N., DiSesa VJ., Strom BL. Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass. //J. Am. Coll. Cardiol. 1998. — vol. 32(7). -p. 1916−1922.
- Kimmel SE., Sekers MA., Berlin JA., Goldberg LR., Strom BL. Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting. // J. Clin. Epidemiol. -1998.-vol.51(l).-p. 1−10.
- Klass J, Mehlhorn U, Zilkins K, Kroner A, et al. Impact of hematocrit value after coronary artery surgery on perioperative myocardial infarction rate. // Thorac Cardiovasc Surg. -2002. vol.50(5). — p.259−265.
- Koh MB. Hunt BJ. The management of perioperative bleeding. // Blood Rev. 2003. -vol. 17(3).-p. 179−185
- Koza MJ., Messmore HL., Wallaock ME. et al. Evaluation of a low molecular weight heparin as an anticoagulant in a model of cardiopulmonary bypass surgery. // Thromb. Res. 1993.-vol. 70.-p. 67−72.
- Kreager JA., Devine DV., Greenberg CS. Cytofluorometric identification of plasmin-sensitive factor XHIa binding to platelets. // Thromb. Haemost. 1988. — vol. 60. — p. 8893.
- Kuitunen AH., Hynynen MJ., Vahtera E., Salmenpera MT. Hydroxyethyl starch as a priming solution for cardiopulmonary bypass impairs hemostasis after cardiac surgery. // Anesth. Analg. 2004. — vol. 98(2). — p. 291−297.
- Kwaan HC., Wang J., Boggio LN. Abnormalities in hemostasis in acute promyelocyte leukemia. // Hematol. Oncol. 2002. — vol. 20(1). — p. 33−41.
- Lackner H., Javid JP. The clinical significance of plasminogen level. // Am. J. Clin. Pathol. 1973., — vol.60, -p.175.
- Lee S., Nikai T., Kanata K., Koshizaki M., Nomura T., Saito Y. A case of severe coronary artery spasm associated with anaphylactic reaction caused by protamine administration. // Masui.-2005.-vol. 54(9).-p. 1043−1046.
- Lemmer JH., Whitaker CL., Mark LJ. et al. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. // J. Thorac. Cardiovasc. Syrg. 2002. -vol. 123.-p. 213−217.
- Liu G, McNicol PL, McCall PR, Bellomo R, et al. Prediction of mediastinal drainage after coronary artery bypass surgery. // Anaecth Intensive Care. 2000. — vol.28(4). — p.420−426.
- Liu H., Fleming NW., Moore PG. Anticoagulation for patients with heparin-induced thrombocytopenia using recombinant hirudin during cardiopulmonary bypass. // J. Clin. Anesth. 2002. — vol. 14(6). — p. 452−456.
- Lo B., Fijnheer R., Castigliego D. Borst C. Kalkman CJ. Nierich AP. Activation of hemostasis after coronary artery bypass grafting with or without cardiopulmonary bypass. Anest. Analg. 2004. — vol.99(3). — p.634−640.
- Lubenow N., Selleng S., Wollert HG., Eichler P., Mullejans B., Greinacher A. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. // Ann. Thorac. Surg. 2003. — vol. 75(2). — p. 577−579.
- Mammen E.F., Koets M.N., Washington B.C. Hemostasis changes during cardiopulmonary bypass surgery. // Sem. Thromb. Hemost. 1985. — vol. 11(3). — p. 281−292.
- Mammen EF. Natural proteinase inhibitors in extracorporeal circulation. // Ann. NY Acad. Sci.- 1968.-vol.146.-p. 754.
- Mariani MA, Gu YJ, Boonstra PW, Grandjean JG, van Oeveren W, Ebels T. Procoagulant activity after off-pump coronary operation: is the current anticoagulation adequate? // Ann Thorac Surg. 1999. — vol.67(5). — p. 1370−1375.
- Martin P., Horkay F., Gupta NK., Gebitekin C., Walker DR. Heparin rebound phenomenon much ado about nothing? // Blood Coagul. Fibrinolysis. — 1992. — vol. 3(2). — p. 187−191.
- Martindale SJ., Shayevitz JR., D’Errico C. The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery. // J. Cardivasc. Vase. Anesth. 1996. — vol. 10. — p. 458−463.
- Marx G, Pokar H, Reuter H. The effects of aprotinin on hemostatic function during cardiac surgery. // J Cardiothorac Vase Anesth. 1991. -vol.5 (5). — p.467−474.
- McKenna R. Abnormal coagulasyion in the postoperative period contributing to excessive bleeding. // Med. Clin. North. Am. 2001. — vol. 85, N 5. — p. 1277−1310.
- Mejak BL., Stammers A., Rauch E., Vang S., Viessaman T. A retrospective study on perfusion incidents and safety devices. // Perfusion. 2000. — vol. 15(1). — p. 51−61.
- Merry A.F. Bivalirudin, blood loss, and graft patency in coronary artery bypass surgery. // Semin. Thromb. Hemost. 2004. — vol. 30(3). — p. 337−346.
- Metz S., Reats AS. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding. // Ann. Thorac. Surg. 1990. — vol. 49. — p. 440−444.
- Michelsen LG., Kikura M., Levy JH. et al. Heparinase I (Neutralase) reversal of systemic anticoagulation. // Anesthesiology. 1996. — vol. 85. — p. 339−346.
- Milas B.L., Jobes D.R., Gorman R.C. Management of bleeding and coagulopathy after heart surgery. // Semin. Thorac. Cardiovasc. Surg. 2000. — vol. 12(4). — p. 326−336
- Miyashita T., Nakajima T., Hayashi Y., Kuro M. Hemostatic effects of low-dose protamine following cardiopulmonary bypass. // Am. J. Hematol. 2000. — vol. 64(2). — p. 112−115.
- Mochizuka T., Olson PJ., Szlam F., Ramsay JG., Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. // Anesth. Analg. 1998. — vol. 87(4). — p. 781−785.
- Moller CH, Steinbruchel DA. Platelet function after coronary artery bypass grafting: is there a procoagulant activity after off-pump compared with on-pum psurgery? // Scand Cardiovasc J. 2003. — vol.37(3). — p. 149−153.
- Mora Mangano CT, Neville MJ, Hsu PH, Mignea I, King J, Miller DC. Aprotinin, blood loss, and renal dysfunction in deep hypothermic circulatory arrest. // Circulation. 2001. -vol. 104(12 Suppl 1). -p.1276−1281.
- Morgan MR., Monnet E., Gaynor JS. The effect of differing rates and injection sites on the amount of protamine delivers before detection of hemodynamic alterations in dogs. // Vet. Surg. 2000. — vol. 29(5). — p. 442−448.
- Morrell DF., Jaros GG., Thornington R. Calcium supplementation during cardiopulmonary bypass in paediatric surgery. // S.Afr.Med.J. 1984. — vol. 66(10). — p.367−368.
- Muller N., Popov-Cenic S" Buttner W. et al. Studies of fibrinolytic and coagulations factors during open heart surgery. // Thromb. Res. 1975. — vol/ 7. — p. 589.
- Muszbek L, Yee V.C., Hevessy Z. Blood coagulation factor XIII: structure and function. // Thrombosis Research. 1999. — vol. 94. — p. 271−305.
- Nicholson SC., Keeling DM., Sinclair ME. et al. Heparin pretreatment does not alter heparin requirements dring cardipulmonary bypass. // Br. J. Anaesth. 2001. — vol. 87. — p. 844−847.
- Noora J, Lamy A, Smith KM, Kent R, et al. The effect of oxygenator membranes on blood: a comparison of two oxygenators in open-heart surgery. // Perfusion. 2003. — vol. 18(5). -p.313−320.
- O’Neill JA., Ende N., Collins HA. A quantitative determination of perfusion fibrinolysis. // Surgery. 1966. — vol.60. — p.809.
- Okita Y, Takamoto S, Ando M, Morota T, Yamaki F, Kawashima Y. Is use of aprotinin safe with deep hypothermic circulatory arrest in aortic surgery? Investigations on blood coagulation. // Circulation. 1996. — vol.94(9 Suppl). — p. IIl 77 181.
- Okuyama K., Matsukawa T., Abe F., Kumazava T. Comparative effect on tranexamic acid on the reduction of bleeding during and after cardiac surgery. // Jap. J. Anesthesiol. 1998. — vol.46.-p.861.
- Orchard MA., Goodcheild CS., Prentice CR. et al. Aprotinine reduces cardiopulmonary-induced blood loss and ingibits fibrinolysis without influencing platelets. // Br. J. Haematol. 1993. — vol.85. — p.533.
- Ovrum E., Tanger G., Oystese R., Ringdal M.A., Istad R. Heparin-coated circuits (Duraflo II) with reduced versus full anticoagulation during coronary artery bypass surgery. // J. Card. Surg.-2003.-vol. 18(2).-p. 140−146.
- Palanzo DA, Zarro DL, Montesano RM et al. Effect of Trillium Biopassive Surface coating of the oxygenator on platelet count drop during cardiopulmonary bypass. // Perfusion. -1999.-Vol.14.-p. 473−479.
- Palanzo DA, Zafro DL, Montesano RM, Manley, NJ. Albumin in the cardiopulmonary bypass prime: how little is enough? // Perfusion. 1999. — Vol. 14. — p. 167−172.
- Panos A., Orrit X., Chevalley C., Kalangos A. Dramatic post-cartdiotomy outcome, due to severe anaphylactic reaction to protamine. // Eur. J. Cardiothorac. Surg. 2003. — vol. 24(2).-p. 325−327.
- Paparella D, Brister SJ, Bushaman MR. Coagulation disorders of cardiopulmonary bypass: a review. // Intensive Care Med. 2004. — vol. 30(10). — p. 1873−1881.
- Paramo JA., Rifon J., Lorens R. et al. Intra- and postoperative fibrinolysis in patients undergoing cardiopulmonary bypass surgery. // Haemostasis. 1991. — Vol. 21. — P. 58−64.
- Perkins HA., Osborne JJ., Hurt R. et al. Neutralization of heparin in vivo with protamine: A simple method of estimating the required dose. // J. Lab. Clin. Med. 1956. — vol. 48. -p. 223−226.
- Pifarre R., Babka R., Sullivan HJ., Montoya A., Bakhos M., El-Etr A, Management of postoperative heparin rebound following cardiopulmonary bypass // J. Thorac. Cardiovasc. Surg. 1981. — vol.81(3). — p. 378−381.
- Pifiare R. Bleeding as a complication of cardiopulmonary bypass. In book Management of bleeding in cardiovascular surgery (ed. Piffare R.). Hanley & Belfiis, Inc., Philadelphia. -2000.-p. 1−9
- Piffare R. The importance of proper anticoagulation and heparin neutralization in cardiopulmonary bypass. / In book. Management of bleeding in cardiovascular surgery. Ed. Piffare R. // Hanley & Belftis, Inc., Philadelphia. 2000. — p. 101−105.
- Porsche R., Brenner ZR. Allergy to protamine sulfate. // Heart Lung. 1999. — vol. 28(6). -p. 418−428.
- Porter JM., Silver D. Alterations in fibrinolysis and coagulation associated with cardiopulmonary bypass. // J. Thorac. Cardiovasc. Surg. 1968. — vol. 56. — p. 869
- Potzsch B., Hund S., Madlener K. et al. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. // Thromb. Res. 1997. — vol. 86. — p. 373−383.
- Potzsch B., Hund S., Seelig C. et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass- assessment of the whole blood ecarin clotting time. // Thromb. Haemost. 1997. — vol. 77. — p.920−925.
- Premaratne S., Razzuk A.M. Effects of platelet transfusion on post cardiopulmonary bypass bleeding. // Jpn. Heart J. 2001. — vol. 42(4). — p. 425−433.
- Racanelli A., Fareed J., Walenga JM. et al. Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments. // Semin. Thromb. Hemost.-1985.-vol. 11.-p. 176−189.
- Ralley FE., De Varennes B. Use of heparinase 1 in a patient with protamine allergy undergoing redo myocardial revascularization. // J. Cardiothorac. Vase. Anesth. 2000. -vol. 14(6).-p. 710−711.
- Ranucci M., Ditta A., Boncilli A., Cotza M., carboni G., Brozzi S., Bonifazi C., Tiezzi A. Determination of anthithrombin consumption in cardiac operations requiring cardiopulmonary bypass. // Perfusion. 2004. — vol. 19(1). — p. 47−52.
- Ray M.J., Hawson G.A.T., Just S.J., et al. Relationship of platelet aggregation to bleeding after cardiopulmonary bypass. // Ann. Thorac. Surg. 1994. — vol. 57. — p. 981−986.
- Ray M.J., O’Brein M.F. Comparision of epsilon aminocapronic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost. // Ann. Thorac. Surg. -2001.-N71 (3).-p. 838−843.
- Reed R., Johnson J., Hudson J. The disparity between hypothermic coagulopathy and clotting studies. //J. Trauma.- 1992. vol. 33. — p. 465−470.
- Reiss FC. Anticoagulation management and cardiac surgery in patients with heparin-induced thrombocytopenia. // Semin. Thorac. Cardiovasc. Surg. 2005. — vol. 17(1). — p. 85−96.
- Rhydderch RD, Khan B, Saleh A. Single dose aprotinin in routine cardiac surgery. // Middle East J Anesthesiol. 1993. — vol. 12(3). — p.287−297.
- Rikitake K., Okazaki Y., Natio K., Ohtsubo S., Natsuaki M., Itoh T. Heparininess cardiopulmonary bypass with argatroban in dog. // Eur. J. Cardiothorac. Surg. 2004. -vol. 25(5).-p. 819−824.
- Rooney S.J., Pagano D., Bongolo G., Wong., Bonser R.S. Aprotinin in aortic surgery requiring hypothermia and circulatory arrest. // Eur. J. Cardiothorac. Surg. 1997. — vol. 11 (2).-p. 373−378.
- Royston D. Controversies in the practical use of aprotinin. // In book Anticoagulation, hemostasis and blood conservation in cardiovascular surgery, (ed. Pifarre R.). -Philadelphia, Hanley & Belius. 1993. — p. 147.
- Royston D., Bastrop B. Reduction in post-operation blood loss in patients having open heart reparations using high dose aprotinin (Trujillo) // Anesthesiology. 1987. — Vol. 67, supply. 3 a. — p. A23.
- Saito Y., Imada T., Takagi J. Platelet factor XIII. The collagen receptor? // J. Biol. Chem. -1986.-vol. 261.-p. 1355−1358.
- Salzman WF. Blood platelets and extracorporeal circulation. 11 Transfusion. 1963. -vol.3.-p. 274.
- Santamaria A, Mateo J, Muniz-Diaz E, Oliver A, Murillo J, Litvan H, Souto JC, Fontcuberta J. Platelet function during cardiopulmonary bypass not changed by two different doses of aprotinin. // Haematologica. 2000. — vol.85(4). — p.381−385.
- Saunders CR., Carlisle L., Bick RL. Hydroxyethyl starch versus albumin in cardiopulmonary bypass prime solutions. // Ann.Thorac. Surg. 1982. — vol. 36. — p. 532.
- Schmied H, Kurz A, Sessler D. Mild intraoperative hypothermia increases blood loss and allogeneic transfusion requirements during total hip arthroplasty // Lancet. 1996. — vol. 347, — p.289−292.
- Segers PAM., Heida JF., de Vries I. Clinical evaluation of 9 hollow membrane oxygenators. // Ne SECC Journ. 2001. — Vol. 26. — p. 10.
- Shahian DM., Wallach SR., Bern MM. Open-heart surgery in patients with cold-reactive proteins. // Surg. Clin. North. Am. 1985. — vol. 65. — p.315.
- Shanberge JN., Murato M., Quattrociocchi-Longe T., van Neste L. Heparin-protamine complexes in the production of heparin rebound and other complications of extracorporeal bypass procedures. // Am. J. Clin. Pathol. 1987. — vol. 87(2). — p. 210−217.
- Shenoy S., Harris RB., Sobel M. Development of heparin antagonists with focused biological activity. // Curr. Pharm. Des. 1999. — vol. 5(12). — p. 965−986
- Shigeta O., Kojima H., Jikuya T., Atsumi N., Sakakibara Y., Nagasawa T., Mitsui T. Aprotinin inhibits plasma-induced platelet activation during cardiopulmonary bypass // Circulation. 1997. — vol. 96 (2). — p. 569−574.
- Shirota K, Watanabe T, Takagi Y, Ohara Y, et al. Maintenanceof blood heparin concentration rater then activated clotting time better preserves the coagulation system in hypothermic cardiopulmonary bypass. // Artif Organs. 2000. — vol.24(l). — p.49−56.
- Shore-Lesserson L. Evidence based coagulation monitors: heparin monitoring, thromboelastography, and platelet function. // Sem. Cardiothor. Vase. Anesth. 2005. -vol.9. — N 1.-p.41−52.
- Shore-Lesserson L., Manspeizer HE., Bolastig M. et al. Anticoagulation for cardiac surgery in patients receiving preoperative heparin: use of the high-dose thrombin time. // Anesth. Analg. 2000. — vol. 90. — p. 813−818.
- Shore-Lesserson L., Reich DL., DePerio M. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. // Can. J. Anaesth. 1998. — vol. 45(1). -p. 10−18.
- Shore-Lesserson L., Reich DL., Vela-Cantos F. et al. Tranexamic acid reduces transfusions and mediastinal drainage in repeat cardiac surgery. // Anest. Analg. 1996. -vol.83. — p. 18.
- Signori EE., Penner JA., Kahn DR. Coagulation defects and bleeding in open-heart surgery. //Ann. Thorac. Surg. 1969. — vol. 8. -p.521.
- Silveira FM" Lourenco DM., Maluf M. et al. Hemostatic changes in children treated with open heart surgery with cardiopulmonary bypass. // Arquivos Brasileiros de Cardiologia. -1998.-vol. 70.-p. 29
- Speekenbrink R. G, Vonk ABA, Wildevuur CRH, Eijsman L. Hemostatic efficacy of dipyridamole, tranexamic acid and aprotinin in coronary bypass gfafting. // Ann Thorac Surg. 1995. — vol.59, -p.438−442.
- Speekenbrink RG, Wildevuur CR, Sturk A, Eijsman L. Low-dose and high-dose aprotinin improve hemostasis in coronary operations. // J Thorac Cardiovasc Surg. 1996. -vol.112(2).- p.523−530.
- Stamatakis J.D., Lawrence D., Kakkar V.V. Surgery, venous thrombosis and anti-Xa. // Br. J. Surg. 1977. — vol. 64. — p. 709−711.
- Stass S., Bishop C. Fosberg R. et al. Platelets as affected by cardiopulmonary bypass. // Trans. Am. Soc. Clin. Pathol. 1976. — p.35.
- Straub A, Azevedo R, Beierlein W, Wendel HP, et al. Hypothermia-induced platelet aggregation: no effect of aprotinin (trasylol) but ingibition by eptifibatide (integrilin). // Thorac Cardiovasc Surg. 2005. — vol.53(2). — p.80−84.
- Subramaniam P., Skilington P., Tatoulis J. Heparin-rebound in the early postoperative phase following cardiopulmonary bypass. // Aust. N. Z. J. Surg. 1995. — vol. 65(5). — p. 331−333.
- Sundt TM III, Kouchoukos NT, Saffitz JE, et al. Renal disfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. // Ann Thorac Surg. 1993. -vol.55.-p.1418−1424.
- Svenarud P., Ovrum E. Clinical effects of different protamine doses after cardiopulmonary bypass. // Asisan Cardiovasc. Thorac. Ann. 2002. — vol. 10(2). — p. 119−123.
- Tabuchi N., Njo TL., Tigchelaar I. et al. Monithoring of anticoagulation in aprotinin-treated patients during heart operation. // Ann. Thorac. Surg. 1994. — vol. 58. — p. 774 777.
- Tanaka K., Wada K., Morimoto T., Shomura S., Nasu M., Okada Y., Yada I., Yuasa H., Kusagawa M. Hemostatic alterations caused by ventricular assist devices for postcardiotomy heart failure. // Artif. Organs. 1991. — vol. 15(1). — p. 59−65.
- Tao W., Deyo DJ., Alpard SK., Vertress RA., Hoang V., Zwischenberger JB. Significant reduction in circuit pressure with modified plasma separation chamber for a heparin removal device. // ASAIO J. 1999. — vol. 45(1). — p. 50−52.
- Tao W., Deyo DJ., Brunston RL. Jr., Vertress RA., Zwischenberger JB. Extracorporeal heparin adsorption following cardiopulmonary bypass with a heparin removal device an alternative to protamine. // Crit. Care Med. — 1998. — vol. 26(6). — p. 1096−1102.
- Teon KH., Young E., Blackall MH., Roberts RH., Hirsh J. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? // J. Thorac. Cardiovasc. Surg. 2004. — vol. 128(2). — 211−219.
- Teufelbauer H, Priodl S., Havel M., Vuckovich T. Early activation of hemostasis during cardiopulmonary bypass: Evidence for thrombin mediated hyperfibrinolysis. // Thromb. Haemost. 1992. — Vol. 68. — P. 250−252.
- Teylor KM. Effect of aprotinin on blood loss and blood use after cardiopulmonary bypass. // In book Anticoagulation, hemostasis and blood conservation in cardiovascular surgery, (ed. Pifarre R.). Philadelphia, Hanley & Belfus. — 1993. — p. 129.
- Tice DA. Worth MH. Recognition and treatment of postoperative bleeding associated with openheart surgery. // Ann. NY Acad. Sci. 1968. -vol.146, -p.745.
- Tigchelaar I., Gallandat Huet RC., Boonstra PW., van Oeveren W. Comparision of three plasma expanders used as priming fluids in cardiopulmonary bypass patients. // Perfusion. 1998. — vol. 13(5). — p. 297−303.
- Tofaletti JG., McDonnell E. Comparisons of activated clotting times (ACT) between Hemochron 801 and Helena Actalyke-Max ACT systems. // AACC Symposium: Crit. Care and Point of Care Testing. 2002. — 12−14 Sept., Monterey, California. — p.97.
- Trieb J., Haass A., Pindur G. Coagulation disorders caused by hydroxyethyl starch. // Thromb. Haemost. 1997. — vol. 78. — p. 974−983.
- Trimble AS., Herse R., Grady M., Crookston J. Blood loss in open heart surgery. // Arch. Surg.-1966.-vol. 93,-p.323.
- Tsuji HK., Redington JV., Kay JH., Goesswald RK. The study of fibrinolytic and coagulation factors during open heart surgery. // Ann. NY Acad. Sci. 1968. — vol.146. -p.763.
- Urdaneto F., Lobato FB., Kirby RR., Horrow JC. Noncardiogenic pulmonary edema associated with protamine administration during coronary artery bypass graft surgery. // J. Clin. Anesth. 1999. — vol. 11(8). — p. 675−681.
- Valen G., Eriksson E., Risberg B., Vaage J. Fibrinolysis during cardiac surgery. Release of tissue plasminogen activator in arterial and coronary sinus blood. // Eur. J. Cardiothorac. Surg. 1994. — Vol. 8. — p. 324−330.
- Valeri CR, Feingold H, Cassidy G, et al: Hypothermia-induced reversible platelet dysfunction. // Ann Surg. 1987. — Vol. 205. — p. 175−181.
- Wahba A, Rothe G, Lodes H, Barlage S, Schmitz G. The influence of the duration of cardiopulmonary bypass on coagulation, fibrinolysis and platelet function. // Thorac Cardiovasc Surg. 2001. — vol.49 (3). — p. 153−156.
- Walenga JM., Bick RL. Heparin-induced thrombocytopenia, paradoxical tromboembolism, and other side effects of heparin therapy. // Med. Clin. North Am. 1998. — vol.82. — p.635
- Walenga JM., Fareed J., Messmore HL. Newer avenues in the monitoring of antithrombotic therapy: the role of automation. // Semin. Thromb. Hemost. 1983. — vol. 9.-p. 346−354.
- Walenga MJ., Koza MJ., Park SJ. et al. Evaluation of CGP 39 393 as the anticoagulant in cardiopulmonary bypass operation in a dog model. // Ann. Thorac. Surg. 1994. — vol. 58. -p. 1685−1689.
- Wang JS., Lin CY., Hung WT., Karp RB. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin. // Anesthesiology. 1992. — vol. 77. — p. 1080−1084.
- Wang JS., Lin CY., Karp RB. Comparison of high-dose thrombin time with activated clotting time of monitoring of anticoagulant effects of heparin in cardiac surgical patients. // Anesth. Analg. 1994. — vol. 79. — p. 9−13.
- Wei M, Kuukasjarv P, Laurikka J, Pehkonen E, Kaukinen S, Honkonen EL, Moilanen E, Tarkka M. Cardioprotective effect of pump prime aprotinin in coronary artery bypass grafting. // Cardiovasc Drugs Ther. 2002. — vol.(l). -p.37−42.
- Weinstein M, Ware JA., Troll J., Salzman EW. Changes in von Willebrand factor during cardiac surgery: effect of desmopressin acetate. // Blood. 1988.- vol.71. — p. 1648.
- Westaby S. Anti-fibrinolytic therapy in thoracic aortic surgery. // Ann Thorac Surg. 1999. -vol.67(6).-p. 1983−1985.
- Westaby S. Coagulation disturbance in profound hypothermia: the influence of antifibrinolytic therapy. // Semin Thorac Cardiovasc Surg. 1997. — vol. 9(3). — p. 246 256.
- Westaby S. Regarding Thoracic and thoracoabdominal aorta aneurism repair using cardiopulmonary bypass, profound hypothermia and circylatory arrestvia left side chest incision. //J Vase Surg. -1999. vol.30(l). -p.196−197.
- Whrittem CW., Greilich PE., Ivy R., Burkhardt D., Allison PM. D-dimer formation during cardiac and noncardiac thoracic surgery. // Anesth. Analg. 1999. — vol. 88 (6). — p. 12 261 231.
- Williams G.D., Bratton S.L. Coagulation tests during cardiopulmonary bypass correlate with blood loss in children undergoing cardiac surgery. // J. Cardiothorac. Vase. Anesth. -1999.-vol. 13(4).-p. 398−404.
- Wong BI. Synthetic antifibrinilytics and aprotinin for cardiac surgery. / In book. Management of bleeding in cardiovascular surgery. Piffare R. (ed) // Hanley&Belfus, Inc., Philadelphia. -2002. p. 261−278.
- Wright TA., Darte J., Mustard WT. Postoperative bleeding after extracrporeal circulation. // Can. J. Surg. 1959. -vol. 2. — p. 142.
- Wyss M, Babel JF, Rouge JC, Bouvier CA. Hemostatic changes during open heart surgerywith extracorporeal circulation and deep hypothermia in children. // Anaesthesist. -1982.-vol.31 (2).-p.82−86.
- Yau TM., Carson S., Weisel RD. The effect of warm heart surgery on postoperative bleeding. // J Thorac Cardiovasc Surg. 1992. — vol. 103. — p. l 155−1163.
- Ygge J. Changes in blood coagulation and fibrinolysis during postoperative period. // Fm. J. Surg. 1970. — vol.119. -p.225.
- Yoshihara H., Yamamoto T., Mihara H. Changes in coagulation and fibrinolysis occurring in dogs during hypothermia. // Thromb. Res. 1985. — vol. 37(4). — p. 503−512.
- Young JA., Kisker CT., Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. // Ann. Thorac. Surg. 1978. — vol. 26.- p. 231−240.